- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Nanotechnology
Volume 2014 (2014), Article ID 854018, 7 pages
Pharmacokinetic and Tissue Distribution Study of Solid Lipid Nanoparticles of Zidovudine in Rats
Department of Pharmaceutics, Indian Institute of Technology, (Banaras Hindu University), Varanasi 221005, India
Received 31 July 2013; Revised 27 December 2013; Accepted 31 December 2013; Published 19 February 2014
Academic Editor: Jeffery L. Coffer
Copyright © 2014 Shah Purvin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M. A. Fischl, D. D. Richman, N. Hansen et al., “The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial,” Annals of Internal Medicine, vol. 112, no. 10, pp. 727–737, 1990.
- G. J. Veal and D. J. Back, “Metabolism of zidovudine,” General Pharmacology, vol. 26, no. 7, pp. 1469–1475, 1995.
- S. Singh, A. K. Dobhal, A. Jain, J. K. Pandit, and S. Chakraborty, “Formulation and evaluation of solid lipid nanoparticles of a water soluble drug: zidovudine,” Chemical and Pharmaceutical Bulletin, vol. 58, no. 5, pp. 650–655, 2010.
- J. das Neves, M. M. Amiji, M. F. Bahia, and B. Sarmento, “Nanotechnology-based systems for the treatment and prevention of HIV/AIDS,” Advanced Drug Delivery Reviews, vol. 62, no. 4-5, pp. 458–477, 2010.
- P. S. Kim and S. W. Read, “Nanotechnology and HIV: potential applications for treatment and prevention,” Wiley Interdisciplinary Reviews, vol. 2, no. 6, pp. 693–702, 2010.
- R. Mallipeddi and L. C. Rohan, “Progress in antiretroviral drug delivery using nanotechnology,” International Journal of Nanomedicine, vol. 5, no. 1, pp. 533–547, 2010.
- P. R. Ravi, U. K. Kotreka, and R. N. Saha, “Controlled release matrix tablets of zidovudine: effect of formulation variables on the in vitro drug release kinetics,” AAPS PharmSciTech, vol. 9, no. 1, pp. 302–313, 2008.
- A. Kuksal, A. K. Tiwary, N. K. Jain, and S. Jain, “Formulation and in vitro, in vivo evaluation of extended-release matrix tablet of zidovudine: influence of combination of hydrophilic and hydrophobic matrix formers,” AAPS PharmSciTech, vol. 7, no. 1, pp. E1–E9, 2006.
- C. D. Kaur, M. Nahar, and N. K. Jain, “Lymphatic targeting of zidovudine using surface-engineered liposomes,” Journal of Drug Targeting, vol. 16, no. 10, pp. 798–805, 2008.
- N. C. Phillips and C. Tsoukas, “Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome,” Blood, vol. 79, no. 5, pp. 1137–1143, 1992.
- S. Jain, A. K. Tiwary, and N. K. Jain, “PEGylated elastic liposomal formulation for lymphatic targeting of zidovudine,” Current Drug Delivery, vol. 5, no. 4, pp. 275–281, 2008.
- U. Y. Nayak, S. Gopal, S. Mutalik et al., “Glutaraldehyde cross-linked chitosan microspheres for controlled delivery of Zidovudine,” Journal of Microencapsulation, vol. 26, no. 3, pp. 214–222, 2009.
- K. Abu-Izza, L. Tambrallo, and D. R. Lu, “In vivo evaluation of zidovudine (AZT)-loaded ethylcellulose microspheres after oral administration in beagle dogs,” Journal of Pharmaceutical Sciences, vol. 86, no. 5, pp. 554–559, 1997.
- H. Hillaireau, T. Le Doan, M. Appel, and P. Couvreur, “Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages,” Journal of Controlled Release, vol. 116, no. 3, pp. 346–352, 2006.
- Y.-C. Kuo and H.-H. Chen, “Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier,” International Journal of Pharmaceutics, vol. 327, no. 1-2, pp. 160–169, 2006.
- R. M. Mainardes, M. P. D. Gremião, I. L. Brunetti, M. D. Luiz Fonseca, and N. M. Khalil, “Pharmaceutical nanotechnology zidovudine-loaded PLA and PLA-PEG blend nanoparticles: influence of polymer type on phagocytic uptake by polymorphonuclear cells,” Journal of Pharmaceutical Sciences, vol. 98, no. 1, pp. 257–267, 2009.
- R. Löbenberg, L. Araujo, H. Von Briesen, E. Rodgers, and J. Kreuter, “Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats,” Journal of Controlled Release, vol. 50, no. 1–3, pp. 21–30, 1998.
- R. M. Mainardes, N. M. Khalil, and M. P. D. Gremião, “Intranasal delivery of zidovudine by PLA and PLA-PEG blend nanoparticles,” International Journal of Pharmaceutics, vol. 395, no. 1-2, pp. 266–271, 2010.
- A. Dembri, M.-J. Montisci, J. C. Gantier, H. Chacun, and G. Ponchel, “Targeting of 3′-azido 3′-deoxythymidine (AZT)-loaded poly(isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissues,” Pharmaceutical Research, vol. 18, no. 4, pp. 467–473, 2001.
- P. M. Ved and K. Kim, “Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal zidovudine delivery to the brain,” International Journal of Pharmaceutics, vol. 411, no. 1-2, pp. 1–9, 2011.
- S. T. K. Narishetty and R. Panchagnula, “Transdermal delivery system for zidovudine: in vitro, ex vivo and in vivo evaluation,” Biopharmaceutics and Drug Disposition, vol. 25, no. 1, pp. 9–20, 2004.
- M. E. Brewster, W. R. Anderson, A. I. Webb et al., “Evaluation of a brain-targeting zidovudine chemical delivery system in dogs,” Antimicrobial Agents and Chemotherapy, vol. 41, no. 1, pp. 122–128, 1997.
- Y. Jin, N. Qi, L. Tong, and D. Chen, “Self-assembled drug delivery systems. Part 5: self-assemblies of a bolaamphiphilic prodrug containing dual zidovudine,” International Journal of Pharmaceutics, vol. 386, no. 1-2, pp. 268–274, 2010.
- S. Chakraborty, D. Shukla, B. Mishra, and S. Singh, “Lipid—an emerging platform for oral delivery of drugs with poor bioavailability,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 73, no. 1, pp. 1–15, 2009.
- A. Zur Mühlen, C. Schwarz, and W. Mehnert, “Solid lipid nanoparticles (SLN) for controlled drug delivery—drug release and release mechanism,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 45, no. 2, pp. 149–155, 1998.
- R. H. Müller, K. Mäder, and S. Gohla, “Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, no. 1, pp. 161–177, 2000.
- M. Uner and G. Yener, “Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives,” International Journal of Nanomedicine, vol. 2, no. 3, pp. 289–300, 2007.